![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Molecular and Cellular Biology, September 2003, p. 6063-6074, Vol. 23, No. 17
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.17.6063-6074.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Molecular Pharmacology and Experimental Therapeutics,1 Department of Biochemistry and Molecular Biology and Molecular Neuroscience Program, Mayo Clinic and Foundation, Rochester, Minnesota 559052
Received 13 March 2003/ Returned for modification 22 April 2003/ Accepted 8 May 2003
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
FEN-1 is a structure-specific nuclease that participates in DNA replication and repair (39). Flap endonuclease (human FEN-1 and/or Saccharomyces cerevisiae Rad27 protein) is required for normal maturation of Okazaki fragments during replication (31, 39, 49, 68). FEN-1 has also been implicated in several repair processes, including base excision repair (BER) (13, 32, 33, 47, 49, 56, 64), nonhomologous end joining (70), recombination (46), nucleotide excision repair (NER) (57), and removal of bulky UV lesions by an alternative excision pathway (72). The details of the steps by which flap endonuclease protects cells from repeat instability or causes expansion remain unclear. However, yeast lacking Rad27 shows both an increased rate of expansion of trinucleotide repeats (15, 52, 60) and duplications flanked by direct repeats (29, 62, 71). These data have been used to support the notion that defective flap processing plays an important causative role in expansion. The failure of FEN-1 to process flaps folded into aberrant hairpin structures is thought to cause expansion at CAG repeats (26, 60). FEN-1 is inhibited by hairpins comprising CAG triplets, because the 5' end needed for FEN-1 loading is concealed within the hairpin structure (26, 60).
Despite the compelling data that loss of yeast Rad27 causes expansion, the relevance to human instability is uncertain. The human FEN-1 and yeast Rad27 protein are homologous, and the human enzyme can complement the defect of yeast null for Rad27 protein (22, 23). Yet the features of expansion induced by loss of Rad27 in yeast are very different from those observed in human disease.
In yeast, expansions are rare compared to deletions, while in human diseases, expansions exceed contractions (16, 42-44, 52). Deletion of Rad27 from yeast causes a severe growth defect at 37°C, instability throughout the genome (mutator phenotype), and increased recombination (30, 45, 61, 62). In mammals, however, loss of FEN-1 is embryonically lethal (37). In human expansion disease, there is neither exchange nor alterations of flanking sequence around the CAG expanded repeat region, suggesting that expansion is not associated with increased homologous recombination. Further, in human repeat expansion, the mutation is limited to a single site (20), inconsistent with a mutator phenotype as occurs with the loss of flap endonuclease in yeast (30, 51). Expansion in human disease must, therefore, occur in the presence of a normal FEN-1 protein. The majority of expansion studies of yeast have relied on models from which the flap endonuclease (Rad27 gene product) is absent. Taken together, the features of rad27 null mutants in yeast do not recapitulate many of the features of expansion in mammalian disease. This raises a question as to the role of FEN-1 in expansion in mammals.
We report here studies designed to improve understanding of the role of FEN-1 in repeat instability in mammals. We have crossed a transgenic mouse lacking one functional allele for FEN-1 (37) with transgenic animals harboring an expanded CAG repeat within the human Huntington's disease (hHD) gene (40). Mice heterozygous for FEN-1 develop and reproduce normally, but they have a rapid tumor progression phenotype (37). Experiments using these animals, therefore, have the advantage that expansion in the hHD allele can be evaluated with a reduced level of normal FEN-1 rather than in its absence. Additionally, we evaluated trinucleotide instability of endogenous repeats in human cells stably transformed with a nuclease-defective FEN-1 that retains its ability to support protein-protein interactions.
FEN-1 protects mammalian cells from repeat instability. Expression of nuclease-defective enzyme destabilizes microsatellites. In addition, cells expressing nuclease-defective FEN-1 show aberrant foci containing proteins of break repair and NER pathways.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Plasmids, cell cultures, and transformation. HCC1937, a BRCA1 mutated breast cancer cell line (65), and the HCC1937 + 5' mycBRCA1-revertant line (7, 53, 65) were from J. Chen (Mayo Clinic). HCC1937 and SK-N-MC cells (American Type Culture Collection) were maintained in RPMI 1640-10% fetal calf serum. wt FEN-1 cDNA with a hemagglutinin [HA] epitope tag encoded at the 3' end and D181A mutant FEN-1 cDNA were gifts of M. S. Park (Los Alamos National Laboratory). The coding region for nuclease-deficient FEN-1 D181A contains a C-for-A substitution at nt 542, which changes codon 181 from GAC (aspartate) in the wt to GCC (alanine) (54-56) (see Fig. 2.) A 625-bp Bpu1102I fragment (nt 433 to 1058) within the FEN-1 D181A coding region was substituted for the Bpu1102I fragment in the wt FEN-1-HA cDNA to create the D181A-HA cDNA. The wt and D181A coding regions were inserted into the vector pcDNA3.1/Hygro (Invitrogen), and plasmids were sequenced to confirm that they differed at the single nucleotide only. Cells were transformed by plasmid DNA-Lipofectamine (Invitrogen). At 24 h after transformation, growth medium was replaced by growth medium supplemented with 100 to 150 µg of hygromycin/ml, a concentration toxic to the SK-N-MC cells. Colonies surviving in a single well were pooled. Using Lipofectamine 2000 (Invitrogen) for transient assays, SK-N-MC cells were cotransformed with the appropriate FEN-1 construct and pEGFP-N1, a green fluorescent protein (GFP) expression vector (Clontech).
|
FEN-1 nuclease activity. For analysis of FEN-1 activity, nuclear extract from FEN-1-transformed and parent SK-N-MC cells was prepared using the method of Andrews and Faller (2), diluted to a final NaCl concentration of 200 mM, and assayed (using the modified Bradford method [Bio-Rad]) for total protein. Flap-1 substrate was used to measure FEN-1 activity in a modification of the previously described assay (24, 60). The reaction mixture included 50 mM Tris-Cl (pH 8), 10 mM MgCl2, 0.5 mM ß-mercaptoethanol, 100 µg of bovine serum albumin (BSA)/ml, 33 µg of sonicated salmon sperm DNA/ml, 80 fmol of 5'-end 32P-labeled substrate, and nuclear extract. The substrate and cleaved product were resolved on 6% sequencing gels and analyzed by PhosphorImager (Molecular Dynamics).
Microsatellite instability assays. SK-N-MC and FEN-transformed cells were harvested, and DNA was purified as described previously (59). Repetitive alleles were amplified using conditions that have been previously described and confirmed by independently repeating the assay (18, 20). For GeneScan (version 3.0; PE Applied Biosystems) analysis, PCR was carried out with a single fluorescein-labeled primer and the products were resolved by polyacrylamide gel electrophoresis. The products were identified by scans of the gel, so that peaks corresponded to DNA molecules. The prominent peak determines the repeat length of the allele. Using values from a GeneScan table, a fraction in a prominent band was calculated for each allele to compare samples. For example, the fraction under peak 191 equals the value for 191 divided by the sum of the values for 191 and 188 [see Fig. 3]). For the ACTC and HD alleles, instability was tested by amplification with alternative sets of primers. For ACTC, the first primer set was 51 to 70 with 140 to 121 (20); the second set was 51 to 70 with 152 to 133 (numbering according to GenBank accession no. HSAC06). For the HD allele, the first primer set was 337 to 366 with 485 to 465 (40); the second set was 308 to 332 with 485 to 465 (numbered according to GenBank accession no. HUMHDA).
|
Immunofluorescence assay of nuclear foci. Anti-FEN-1 (N-17), anti-ERCC1 (FL-297), anti-XPG (N-17), anti-p21 (C-19), anti-CBP (A-22), and anti-Rad51 (H-92) were from Santa Cruz Biotechnology. Anti-rabbit Cy5 was from Amersham. Anti-goat Cy5 was from Zymed. Cells were plated on coverslips in the wells of 6-well dishes 1 day before drug treatment. Cisplatin stock (2 mM) was prepared in PBS and added (15 µM final concentration) to cultures at the indicated time before time zero. At time zero, coverslips were washed with PBS, fixed in ice-cold methanol, washed, and then incubated sequentially in blocking buffer (Tris-buffered saline [TBS] containing 0.02% Tween 20 [Sigma], 5% skim milk [Difco], 5% BSA [Roche]) and in primary antibody diluted in blocking buffer. Cells were washed in TBS-0.02% Tween 20 and then incubated in secondary antibody conjugated to Cy5. The integrity of compartments and primary antibody-dependent staining was confirmed (see Results and Fig. 5). As a control for primary antibody specificity, mock experiments in which a primary antibody raised in a different species was used with the same secondary antibody were carried out in parallel (see Fig. 5). Coverslips were then washed in TBS-0.02% Tween 20, in TBS, and in water containing 0.2 µg of Hoechst 33258/ml to stain nuclei. To estimate the number of nuclear foci, coverslips were examined for Cy5 fluorescent dots within the area of Hoechst staining. Foci in 50 unselected nuclei were counted. The average number is reported (± the standard error of the mean [SEM]).
|
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
Previous studies with R6/1 mice have revealed that repeats appear to be stable in somatic tissues until 11 weeks but that expansion occurs with aging (35, 40, 41). The degree of age-dependent expansion varies with the tissue type (35, 40, 41). We therefore examined tissues of littermates at 21 weeks of age to determine whether the degree of somatic instability differs depending on FEN-1 genotype. However, we found no significant differences in CAG repeat length in the hHD allele among tissues from FEN-1+/-/hHD+/- and FEN-1+/+/hHD+/- littermates sacrificed at different ages. Therefore, CAG repeats in somatic cells did not show FEN-1 genotype-dependent changes (Fig. 1C). FEN-1 effects on instability in progeny were limited to the developing germ cells.
Analyses of mice, then, indicate that haploinsufficiency of FEN-1 can alter trinucleotide repeat length stability by inhibiting the frequency of deletion events and modestly increasing expansion events at long disease-length alleles in mammals. In mice, expansion occurs in the haploid germ cells in the process of repair (35). FEN-1 effects on instability may also arise during repair.
Expression of nuclease-defective FEN-1 in human cells. To test the hypothesis that deficient FEN-1 activity could create precursors to expansion, we created a stable human cell line transformed with nuclease-defective FEN-1 (54, 55) (Fig. 2A). Normal levels of wt enzyme are present, but the mutant can bind and interfere with processing by the wt enzyme at some flaps.
SK-N-MC cells were stably transformed with an expression vector containing the cDNA for nuclease-deficient FEN-1 (54, 55) fused to an HA tag (Fig. 2B). The mutant FEN-1 contains a single aspartate-to-alanine change (D181A) in its nuclease domain (Fig. 2A) (see Materials and Methods). This amino acid change does not alter binding of FEN-1 to its DNA substrate but does eliminate the endonuclease catalytic activity there (54, 55). Stable transformants contained wt and nuclease-defective FEN-1 with structure-dependent affinity for displaced strands. wt FEN-1 can efficiently cleave at the flap junction, leaving a substrate for DNA ligase (Fig. 2C) (27). However, binding of the nuclease-deficient FEN-1 at the substrate can cause failure to cleave the flap and thereby leave a precursor either to expansion or to a strand break (Fig. 2D). The coexpression of the mutant FEN-1 in the SK-N cells was expected to produce a competition with wt enzyme for binding to the flap template (Fig. 2D).
Transformed cells were analyzed for exogenous protein expression (Fig. 2B) and FEN-1 nuclease activity (Fig. 2E). Immunoblot analysis using anti-HA antibody showed that a protein of the appropriate size (the predicted mass of FEN-HA fusion protein is 44,164 Da) was detected in whole-cell extract from hygromycin-resistant cells but not in control parent cells (SK-N) (Fig. 2B). These data confirmed that the mutant enzyme was efficiently expressed in the human cell lines. The level of wt enzyme appears to be regulated in cells, since levels of the mutant enzyme were consistently higher than those of the exogenous wt enzyme in independent clones (Fig. 2B).
We tested extracts from stably transformed SK-N-MC cells to investigate whether expression of the nuclease-deficient FEN-1 inhibited flap processing. FEN-1 activity was measured in vitro by incubating a Flap-1 substrate (Fig. 2E, top panel) in the presence or absence of nuclear extract from the transformed cells (see Materials and Methods). FEN-1 cleaves at either base adjacent to the junction of the displaced strand, leaving fragments of 19 and 21 nt (Fig. 2E) (24, 60). FEN-1 D181A binds as well as the wt but does not cleave (54-56).
If nuclease-defective FEN-1 in extracts imparted a dominant-negative effect, then its presence might substantially lower FEN-1 cleavage activity by binding to substrate and interfering with processing by endogenous enzymes. Despite robust expression of the mutant FEN-1 enzyme (Fig. 2B), however, we found no apparent decrease in FEN-1 cleavage activity in the model template in any of the D181A-transformed cells compared to levels in the parent SK-N-MC (Fig. 2E). Although contribution of another endonuclease to the total activity cannot be ruled out, the pattern of cleavage is identical to that of FEN-1 previously reported in both purified form and in cell lysates (24, 60). Therefore, the concentration of normal enzyme in vitro is sufficient to carry out cleavage in the presence of nuclease-defective FEN-1. In vivo, however, FEN-1 must distribute throughout the genome and particular sites might be sensitive to the presence of the nuclease-defective enzyme. Therefore, we tested whether expression of the mutant FEN-1 caused a selective and/or subtle phenotype in vivo.
Human cells expressing nuclease-defective FEN-1 are susceptible to cell death. We found that expression of the nuclease-deficient FEN-1 impaired survival. To measure the effects of nuclease-defective FEN-1 in human cells, we cotransformed SK-N-MC cells with GFP and FEN-1 expression vectors and monitored the survival of green cells. For transformants expressing the exogenous wt enzyme, we found no obvious effect on cell survival (Fig. 2F). The number of green cells in the FEN wt culture was similar to that in the SK-N-MC culture as late as 72 h after transfection. In contrast, expression of the nuclease-defective FEN-1 rendered cells more susceptible to death as early as 20 h after transfection, as indicated by the lower number of GFP-positive cells in cultures expressing nuclease-defective FEN-1 (Fig. 2F). Thus, the nuclease-defective enzyme caused the increase in cell death.
Expression of nuclease-defective FEN D181A causes repeat instability. We hypothesize that site-specific failure to process flaps can cause repeat instability (Fig. 2D). The nuclease-defective FEN D181A should bind at some flaps, thereby interfering with cleavage by the endogenous wt enzyme and leaving a precursor for expansion (Fig. 2D). We tested whether expression of the nuclease-deficient enzyme can alter the stability of repeat tracts of several endogenous loci (Table 2) (18, 20) (see Materials and Methods). Two of the examined loci (Sca1 and HD) are associated with trinucleotide repeat diseases, and three of the loci (ACTC, D6S305, and D6S264) have been shown to be unstable in colon tumors (20). In normal cells, however, all of these microsatellites are stable (as is confirmed by their usefulness as highly informative markers for genetic analysis) (34).
|
In the GeneScan method, repeat-containing regions are PCR amplified using one primer that is fluorescein labeled. The lengths of DNA products can be determined after resolution on denaturing polyacrylamide gels, and each amplified product is seen as a peak in the GeneScan trace (35, 36) (Materials and Methods). At the HD allele, for example, separation of the two prominent peaks in SK-N-MC cells indicates that the long and short HD alleles differ by 9 bp or three repeats (Fig. 3A, HD [right panel]). Alterations in repeat length cause changes in the sizes of PCR product. Since repeat lengths change by a discrete number of nucleotides, peaks that shift position are often coincident with another peak in the trace. Thus, repeat length changes are identified either as the appearance of a new peak or by changes in peak areas (Fig. 3A; compare results for parent SK-N-MC and D181A).
Amplification of repeat-containing regions typically yields a prominent band with adjacent smaller bands (Fig. 3A) (20, 69). SK-N-MC and FEN wt-transformed cultures are indistinguishable by microsatellite analysis. Reproducible deviations from the parental pattern were detected in D181A cultures at two test loci, ACTC (a microsatellite within the gene encoding cardiac muscle actin) and HD (Table 2; Fig. 3A). Changing peak areas within the GeneScan traces indicated that in the D181A sample, there were numbers of repeats different from those in the SK-N-MC parent or FEN wt at both loci (Fig. 3A). To confirm that the altered patterns were due to repeat-length changes within the target gene, both the ACTC and HD alleles were amplified with two different primer sets (primer 1 and primer 2) (Fig. 3A). For both ACTC and HD, amplification with alternative primer sets yielded the same pattern of products but shifted by the appropriate distance (Fig. 3A; results are shown for ACTC only [compare primer 1 and primer 2 results]). Thus, the observed microsatellite instability within the PCR products was gene specific.
At both ACTC alleles and the long HD allele in D181A-transformed cultures, the ratio of the prominent peak area (Fig. 3A) is altered relative to that of the secondary peak in the trace (Fig. 3A). Using both sets of primers (Fig. 3B to D), we calculated the fraction under the prominent peak (most-abundant repeat length) for the ACTC alleles and the long HD allele in independent amplification reactions (Fig. 3B to D). The analysis demonstrates that the repeat length of one HD allele was indistinguishable among the SK-N-MC and FEN wt-transformed cultures but differed significantly in FEN D181A-transformed cultures (P < 0.0001) (Fig. 3B to D). Both sets of primers yielded similar results, indicating that the repeat lengths reflected a property of the specific alleles (Fig. 3B and C). As an internal control, we found that the shorter HD allele was the same in all of the samples (Fig. 3D).
Therefore, expression of nuclease-defective FEN-1 is sufficient to cause microsatellite instability. An uncleaved flap may be a direct precursor to instability and may disrupt repair activities in transformed cells.
Expression of nuclease-deficient FEN-1 causes a reduced capacity to correct strand breaks. Experiments with nuclease-defective FEN-1 confirmed that repair of displaced flaps is essential for genome stability (Fig. 3). Instability must, therefore, arise from faulty repair of flaps. To test relevant processing events, we treated cells with DNA-damaging agents that might directly or indirectly create flaps. MMS increases the number of alkylated bases, which are typically repaired by BER (10). BER causes single-strand DNA breaks in the process of removal of alkylated bases, and this process can be FEN-1 dependent (13, 32, 33, 47, 49, 56, 64). However, in cell cultures, a high degree of MMS-mediated single-strand breaks can also result in double-strand breaks (66).
We also used cisplatin to induce strand breaks. Cisplatin creates bulky lesions that can be removed by NER (3, 10, 11, 28). Cisplatin can also form interstrand cross-links that are corrected by double-strand break repair (4, 73). After either treatment, survival of drug-treated cells was measured by colony survival assay (Materials and Methods).
Expression of the exogenous wt FEN-1 and D181A FEN-1 caused cells to be hypersensitive to MMS (Fig. 4A) compared to the parent SK-N-MC cells. However, cells expressing the nuclease-defective FEN-1 did not differ in MMS sensitivity relative to the cells exogenously expressing wt FEN-1 (Fig. 4A). The activity of FEN-1 is regulated by its direct interaction with many cellular enzymes, including proliferating cell nuclear antigen, a DNA polymerase 
, and 
processivity factor (14, 19, 22, 31, 38, 39, 56, 63, 64, 68); the transcriptional coregulator and acetylase P300 (25); and the WRN helicase (6). Furthermore, the cell cycle regulator p21waf1/CIP shares a proliferating cell nuclear antigen interaction domain with FEN-1 (64, 67), and the competition between FEN-1 and p21 modulates the response to DNA damage (64). That cells expressing wt and nuclease-defective FEN-1 were equally susceptible to MMS suggests that the levels of exogenous protein (expressed under control of the cytomegalovirus promoter) can disrupt the protein-protein interactions required for proper cellular metabolism.
|
Defective flap processing blocks assembly of Rad51/BRCA1 in repair foci after cisplatin treatment. We hypothesized that expression of the exogenous enzyme might perturb the behavior of key repair enzymes. To test the hypothesis, we analyzed the recruitment of repair proteins to nuclear foci. Fixed cells (see Materials and Methods) were incubated with specific antibodies to identify components of nuclear foci. Analyses of control proteins confirmed that they were present in the correct subcellular compartment. Cells were treated and images were taken in parallel under identical conditions, with the exception of the primary antibody. For example, CREB binding protein, ERCC1, and p21 showed distinctive patterns and intensities. All utilized the same secondary antibody, which, in the absence of primary antibody, generated no fluorescence signal (Fig. 5A). These data indicated that the signal was specific to the primary antibody under the conditions of our experiments (Fig. 5A to F). The analysis was also able to detect functional differences in subcellular localization. BRCA1 was not detected in the nuclei of HCC1937 cells that lack BRCA1 (Fig. 5E) (7, 53, 65). In contrast, BRCA1 foci were observed in revertant HCC1937 + 5'mycBRCA1 cells that were transformed with functional BRCA1 (Fig. 5F).
To test repair activity of cisplatin lesions, SK-N-MC parent cells and FEN wt and D181A-transformed cells were fixed after treatment and then stained with the appropriate antibodies. In cells expressing exogenous wt FEN-1 or D181A, cisplatin damage caused FEN-1 to be recruited to repair foci in the nucleus (Fig. 5G). Therefore, we monitored repair enzymes that redistributed with FEN-1 under different conditions of flap processing. We hypothesized that relevant repair pathways would be perturbed when the mutant FEN-1 protein was overexpressed.
Rad51 is required for homologous repair and recombination at strand breaks. Previous studies have demonstrated its role in repair of strand breaks and of cisplatin-induced damage (4). We found that at 30 min after cisplatin treatment, recruitment of Rad51 to nuclear foci decreased in the D181A-transformed cells but increased in SK-N-MC and FEN wt-transformed cells (Fig. 6A). These data raised the possibility that FEN-1 plays a role in strand break repair.
|
A substantial body of evidence has shown that NER can remove cisplatin intrastrand cross-links (3, 10, 11, 28). Therefore, we tested whether key components of the NER pathway were recruited to repair foci when flap processing was impaired. ERCC1 forms a nuclease with XPF that cleaves 5' to a bulky lesion (3, 10, 11). We found that within 30 min of cisplatin treatment, there was a marked increase in the number of ERCC1 nuclear foci in D181A-transformed cells (Fig. 6D and 5F). Under the same conditions, cells overexpressing the wt FEN-1 displayed little to no change (Fig. 6C and 5F). It appeared that some components of the NER pathway were recruited to repair foci when flap processing was impaired. For cells deficient in NER (XPC671 cells) (8) (Fig. 6D), in contrast, there was no effect on FEN-1 focus formation relative to control cells (Fig. 6D). The staining of ERCC1 appeared to be specific. We tested other components of the NER pathway. For XPG, focus formation in D181A-transformed cells differed from that of FEN wt-transformed or from parental SK-N-MC cells but with a somewhat different pattern from that seen with ERCC1 (data not shown). The percentage of XPG foci in D181A-transformed cells decreased (56.2% ± 2.0%) relative to parent SK-N cells (74.9% ± 3.5%) and to FEN wt-transformed cells (99.9% ± 5.4%) within 30 min of cisplatin treatment.
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Model for nuclease-defective FEN-1-mediated instability in mammals. The data suggest a model by which FEN-1 maintains genome stability and aberrant FEN-1 processing underlies instability (Fig. 7). Normal processing by FEN-1 removes flaps that might give rise to instability (Fig. 3 and 7A). Although the mechanism of interaction is unknown, FEN-1 repair appears to depend on a complex comprising Rad51 and BRCA1 (Fig. 6B and 7A). Previous studies have not identified a role for FEN-1 in double-strand break repair (56), but Rad51 and BRCA1 are required for repair of cisplatin-induced DNA damage (4, 5). We show here that repair of cisplatin damage also requires functional FEN-1 (Fig. 4B) and that recruitment of FEN-1 depends on BRCA1 (Fig. 6B). Furthermore, defective FEN-1 nuclease activity inhibits recruitment of Rad 51 to repair foci after cisplatin treatment (Fig. 6A). Cells can survive in the presence of the nuclease-defective enzyme, but our studies show that its expression causes a failure to assemble Rad51-containing repair complexes even in the presence of wt FEN-1. This implies that repair in the absence of intact Rad 51 complexes occurs via other pathways (Fig. 5F and 6A).
|
The alternative repair pathway is unlikely to be canonical NER, since XPG focus formation in D181A cells does not follow the same pattern as that of ERCC1 within a similar time frame after cisplatin treatment. ERCC1 has a role in NER but also has other functions in the cell, notably in strand break repair (1). In fact, evidence for a non-NER pathway that involves ERCC1 has been recently reported (12). Chinese hamster ovary lines defective in individual components of NER were unable to repair both cisplatin-induced interstrand and intrastrand cross-links. ERCC1- and XPF-deficient lines were extremely sensitive to cisplatin damage, however, in contrast to lines deficient in other components of NER. Under these conditions, cisplatin adducts did not appear to involve the formation of DNA double-strand breaks. EFCC1-deficient cells cannot support NER. However, the high level of cisplatin sensitivity of ERCC1- and XPF-deficient cells indicates a defect in another pathway, possibly single-strand annealing.
The alternative pathway that gives rise to trinucleotide instability is unclear. However, one of two mechanisms may underlie the mutation. A repair complex may be recruited but fail to excise the hairpin, in which case the hairpin is incorporated into the DNA (Fig. 7B). Alternatively, a repair complex may succeed in excising the hairpin; then extra repeats are incorporated after slippage during repair synthesis (Fig. 7B). Further studies employing multiple repair enzymes will be required to firmly establish a mechanism.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by the Mayo Foundation, the Hereditary Disease Foundation, the National Institutes of Health (DK 43694 and MH56207), and the National Science Foundation (IBN 9728120 [to C.T.M.]).
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
2. Andrews, N. C., and D. V. Faller. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19:2499.
3. Araujo, S. J., F. Tirode, F. Coin, H. Pospiech, J. E. Syvaoja, M. Stucki, U. Hubscher, J. M. Egly, and R. D. Wood. 2000. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 14:349-359.
4. Bhattacharyya, A., U. S. Ear, B. H. Koller, R. R. Weichselbaum, and D. K. Bishop. 2000. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275:23899-23903.
5. Bishop, D. K., U. Ear, A. Bhattacharyya, C. Calderone, M. Beckett, R. R. Weichselbaum, and A. Shinohara. 1998. XRCC3 is required for assembly of Rad51 complexes in vivo. J. Biol. Chem. 273:21482-21488.
6. Brosh, R. M., C. von Kobbe, J. A. Sommers, P. Karmakar, P. L. Opresko, J. Piotrowski, I. Dianova, G. L. Dianov, and V. A. Bohr. 2001. Werner syndrome protein interacts with human flap endonuclease 1 and stimulates its cleavage activity. EMBO J. 20:5791-5801.[CrossRef][Medline]
7. Chen, J., D. P. Silver, D. Walpita, S. B. Cantor, A. F. Gazdar, G. Tomlinson, F. J. Couch, B. L. Weber, T. Ashley, D. M. Livingston, and R. Scully. 1998. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 2:317-328.[CrossRef][Medline]
8. Cleaver, J. E., L. H. Thompson, A. S. Richardson, and J. C. States. 1999. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum. Mutat. 14:9-22.[CrossRef][Medline]
9. Daly, L. E. and G. J. Bourke. 2000. Interpretation and uses of medical statistics, 5th ed. Blackwell Science Ltd., Oxford, United Kingdom.
10. de Boer, J., and J. H. J. Hoeijmakers. 2000. Nucleotide excision repair and human syndromes. Carcinogenesis 21:453-460.
11. de Laat, W. L., N. G. J. Jaspers, and J. H. J. Hoeijmakers. 1999. Molecular mechanism of nucleotide excision repair. Genes Dev. 13:768-785.
12. DeSilva, I. U., P. J. McHugh, P. H. Clingen, and J. A. Hartley. 2002. Defects in intrastrand crosslinks uncoupling do not account for extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res. 30:3848-3856.
13. Dianova, I. I., V. A. Bohr, and G. L. Dianov. 2001. Interaction of human AP endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision. Biochemistry 40:12639-12644.[CrossRef][Medline]
14. Frank, G., J. Qiu, L. Zheng, and B. Shen. 2001. Stimulation of eukaryotic flap endonuclease-1 activities by proliferating cell nuclear antigen (PCNA) is independent of its in vitro interaction via a consensus PCNA binding region. J. Biol. Chem. 276:36295-36302.
15. Freudenreich, C. H., S. M. Kantrow, and V. A. Zakian. 1998. Expansion and length-dependent fragility of CTG repeats in yeast. Science 279:853-856.
16. Freudenreich, C. H., J. B. Stavenhagen, and V. A. Zakain. 1997. Stability of a CTG/CAG trinucleotide repeat in yeast is dependent on its orientation in the genome. Mol. Cell. Biol. 17:2090-2098.[Abstract]
17. Gacy, A. M., G. Goellner, N. Juranic, S. Macura, and C. T. McMurray. 1995. Trinucleotide repeats that expand in human disease form hairpin structures in vitro. Cell 81:533-540.[CrossRef][Medline]
18. Gacy, A. M., G. M. Goellner, C. Spiro, X. Chen, G. Gupta, E. M. Bradbury, R. B. Dyer, M. J. Mikesell, J. Z. Yao, A. J. Johnson, A. Richter, S. B. Melancon, and C. T. McMurray. 1998. GAA instability in Friedreich's ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol. Cell 1:583-593.[CrossRef][Medline]
19. Gary, R., M. S. Park, J. P. Nolan, H. L. Cornelius, O. G. Kozyreva, H. T. Tran, K. S. Lobachev, M. A. Resnick, and D. A. Gordenin. 1999. A novel role in DNA metabolism for the binding of FEN1/Rad27 to PCNA and implications for genetic risk. Mol. Cell. Biol. 19:5373-5382.
20. Goellner, G. M., D. Tester, S. Thibodeau, E. Almqvist, Y. P. Goldberg, M. R. Hayden, and C. T. McMurray. 1997. Different mechanisms underlie DNA instability in Huntington disease and colorectal cancer. Am. J. Hum. Genet. 60:879-890.[Medline]
21. Goldberg, Y. P., C. T. McMurray, J. Zeisler, E. Almqvist, D. Sillence, F. Richards, A. M. Gacy, J. Buchanan, H. Telenius, and M. R. Hayden. 1995. Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum. Mol. Genet. 4:1911-1918.
22. Greene, A. L., J. R. Snipe, D. A. Gordenin, and M. A. Resnick. 1999. Functional analysis of human FEN1 in Saccharomyces cerevisiae and its role in genome stability. Hum. Mol. Genet. 8:2263-2273.
23. Hansen, R. J., E. C. Friedberg, and M. S. Reagan. 2000. Sensitivity of a S. cerevisiae RAD27 deletion mutant to DNA-damaging agents and in vivo complementation by the human FEN-1 gene. Mutat. Res. 461:243-248.[Medline]
24. Harrington, J. J., and M. R. Lieber. 1994. The characterization of a mammalian structure-specific DNA endonuclease. EMBO J. 13:1235-1246.[Medline]
25. Hasan, S., M. Stucki, P. O. Hassa, R. Imhof, P. Gehrig, P. Hunziker, U. Hubscher, and M. O. Hottiger. 2001. Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300. Mol. Cell 7:1221-1231.[CrossRef][Medline]
26. Henricksen, L. A., S. Tom, Y. Liu, and R. A. Bambara. 2000. Inhibition of flap endonuclease 1 by flap secondary structure and relevance to repeat sequence expansion. J. Biol. Chem. 275:16420-16427.
27. Henricksen, L. A., J. Veeraraghavan, D. R. Chafin, and R. A. Bambara. 2002. DNA ligase I competes with FEN1 to expand repetitive DNA sequences in vitro. J. Biol. Chem. 277:22361-22369.
28. Jamieson, E. R., and S. J. Lippard. 1999. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:2467-2498.[CrossRef][Medline]
29. Jin, Y. H., R. Obert, P. M. J. Burgers, T. A. Kunkel, M. A. Resnick, and D. A. Gordenin. 2001. The 3'
5' exonuclease of DNA polymerase delta can substitute for the 5' flap endonuclease Rad27/Fen1 in processing Okazaki fragments and preventing genome instability. Proc. Natl. Acad. Sci. USA 98:5122-5127.
30. Johnson, R. E., G. K. Kovvali, L. Prakash, and S. Prakash. 1995. Requirement of the yeast RTH1 5' to 3' exonuclease for the stability of simple repetitive DNA. Science 269:238-240.
31. Kim, I.-S., M.-Y. Lee, I.-H. Lee, S.-L. Shin, and S.-Y. Lee. 2000. Gene expression of flap endonuclease-1 during cell proliferation and differentiation. Biochim. Biophys. Acta 1496:333-340.[Medline]
32. Kim, K., S. Biade, and Y. Matsumoto. 1998. Involvement of flap endonuclease 1 in base excision DNA repair. J. Biol. Chem. 273:8842-8848.
33. Klungland, A., and T. Lindahl. 1997. Second pathway for completion of human DNA base-excision repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J. 16:3341-3348.[CrossRef][Medline]
34. Korf, B. R., and R. A. Pagon. 2001. Overview of molecular genetic diagnosis, p. 9.2.1-9.2.6. In N. C. Dracopoli, J. L. Haines, B. R. Korf, D. T. Moir, C. C. Morton, C. E. Seidman, J. G. Seidman, and D. R. Smith (ed.), Current protocols in human genetics. John Wiley & Sons, New York, N.Y.
35. Kovtun, I. V., and C. T. McMurray. 2001. Trinucleotide expansion in haploid germ cells by gap repair. Nat. Genet. 27:407-411.[CrossRef][Medline]
36. Kovtun, I. V., T. M. Therneau, and C. T. McMurray. 2000. Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. Hum. Mol. Genet. 9:2767-2775.
37. Kucherlapati, M., K. Yang, M. Kuraguchi, J. Zhao, M. Lia, J. Heyer, M. F. Kane, K. Fan, R. Russell, A. M. C. Brown, B. Kneitz, W. Edelmann, R. D. Kolodner, M. Lipkin, and R. Kucherlapati. 2002. Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression. Proc. Natl. Acad. Sci. USA 99:9924-9929.
38. Li, X., J. Li, J. Harrington, M. R. Lieber, and P. M. J. Burgers. 1995. Lagging strand DNA synthesis at the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating cell nuclear antigen. J. Biol. Chem. 270:22109-22112.
39. Lieber, M. R. 1997. The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. Bioessays 19:233-240.[CrossRef][Medline]
40. Mangiarini, L., K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S. W. Davies, and G. P. Bates. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause progressive neurological phenotype in transgenic mice. Cell 87:493-506.[CrossRef][Medline]
41. Manley, K., T. L. Shirley, L. Flaherty, and A. Messer. 1999. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice Nat. Genet. 23:471-473.
42. Maurer, D. J., B. L. O'Callaghan, and D. M. Livingston. 1996. Orientation dependence of trinucleotide CAG repeat instability in Saccharomyces cerevisiae. Mol. Cell. Biol. 16:6617-6622.[Abstract]
43. McMurray, C. T. 1999. DNA secondary structure: a common and causative factor for expansion in human disease. Proc. Natl. Acad. Sci. USA 96:1823-1825.
44. Miret, J. J., L. Pessoa-Brandão, and R. S. Lahue. 1997. Instability of CAG and CTG trinucleotide repeats in Saccharomyces cerevisiae. Mol. Cell. Biol. 17:3382-3387.[Abstract]
45. Moreau, S., E. A. Morgan, and L. S. Symington. 2001. Overlapping functions of the Saccharomyces cerevisiae Mre11, Exo1 and Rad27 nucleases in DNA metabolism. Genetics 159:1423-1433.
46. Negritto, M. C., J. Qiu, D. O. Ratay, B. Shen, and A. M. Bailis. 2001. Novel function of Rad27 (FEN-1) in restricting short-sequence recombination. Mol. Cell. Biol. 21:2349-2358.
47. Pascucci, B., G. Maga, U. Hubscher, M. Bjoras, E. Seeberg, I. D. Hickson, G. Villani, C. Giordano, L. Cellai, and E. Dogliotti. 2002. Reconstitution of the base excision repair pathway for 7,8-dihydro-8-oxoguanine with purified human proteins. Nucleic Acids Res. 30:2124-2130.
48. Pearson, C. E., A. Ewel, S. Acharya, R. A. Fishel, and R. R. Sinden. 1997. Human Msh2 binds to trinucleotide repeat DNA structures associated with neurodegenerative diseases. Hum. Mol. Genet. 6:1117-1123.
49. Qiu, J., X. Li, G. Frank, and B. Shen. 2001. Cell cycle-dependent and DNA damage-inducible nuclear localization of FEN-1 nuclease is consistent with its dual functions in DNA replication and repair. J. Biol. Chem. 276:4901-4908.
50. Richard, G.-F., G. M. Goellner, C. T. McMurray, and J. E. Haber. 2000. Recombination-induced CAG trinucleotide repeat expansions in yeast involve the MRE11/RAD50/XRS2 complex. EMBO J. 19:2381-2390.[CrossRef][Medline]
51. Sarkar, P. S., H. C. Chang, F. B. Boudi, and S. Reddy. 1998. CTG repeats show bimodal amplification in E. coli. Cell 95:531-540.[CrossRef][Medline]
52. Schweitzer, J. K., and D. M. Livingston. 1998. Expansions of CAG repeat tracts are frequent in a yeast mutant defective in Okazaki fragment maturation. Hum. Mol. Genet. 7:69-74.
53. Scully, R., S. Ganesan, K. Vlasakova, J. Chen, M. Socolovsky, and D. M. Livingston. 1999. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4:1093-1099.[CrossRef][Medline]
54. Shen, B., J. P. Nolan, L. A. Sklar, and M. S. Park. 1996. Essential amino acids for substrate binding and catalysis of human flap endonuclease 1. J. Biol. Chem. 271:9173-9176.
55. Shen, B., J. P. Nolan, L. A. Sklar, and M. S. Park. 1997. Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res. 25:3332-3338.
56. Shibata, Y., and T. Nakamura. 2002. Defective flap endonuclease 1 activity in mammalian cells is associated with impaired DNA repair and prolonged S phase delay. J. Biol. Chem. 277:746-754.
57. Shivji, M. K. K., V. N. Podust, U. Hübscher, and R. D. Wood. 1995. Nucleotide excision repair DNA synthesis by DNA polymerase in the presence of PCNA, RFC and RPA. Biochemistry 34:5011-5017.[CrossRef][Medline]
58. Spiro, C., D. P. Bazett-Jones, X. Wu, and C. T. McMurray. 1995. DNA structure determines protein binding and transcriptional efficiency of the proenkephalin cAMP-responsive enhancer. J. Biol. Chem. 270:27702-27710.
59. Spiro, C., and C. T. McMurray. 1999. Footprint analysis of DNA-protein complexes in vitro and in vivo, p. 27-62. In D. S. Latchman (ed.), Transcription factors: a practical approach, 2nd edition. Oxford University Press, Oxford, United Kingdom.
60. Spiro, C., R. Pelletier, M. L. Rolfsmeier, M. J. Dixon, R. S. Lahue, G. Gupta, M. S. Park, X. Chen, S. V. S. Mariappan, and C. T. McMurray. 1999. Inhibition of FEN-1 processing by DNA secondary structure at trinucleotide repeats. Mol. Cell 4:1079-1085.[CrossRef][Medline]
61. Symington, L. S. 1998. Homologous recombination is required for the viability of rad27 mutants. Nucleic Acids Res. 26:5589-5595.
62. Tishkoff, D. X., N. Filosi, G. M. Gaida, and R. D. Kolodner. 1997. A novel mutation avoidance mechanism dependent on S. cerevisiae RAD27 is distinct from DNA mismatch repair. Cell 88:253-263.[CrossRef][Medline]
63. Tom, S., L. A. Henricksen, and R. A. Bambara. 2000. Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1. J. Biol. Chem. 275:10498-10505.
64. Tom, S., T. A. Ranalli, V. N. Podust, and R. A. Bambara. 2001. Regulatory roles of p21 and apurinic/apyrimidinic endonuclease 1 in base excision repair. J. Biol. Chem. 276:48781-48789.
65. Tomlinson, G. E., T. T. Chen, V. A. Stastny, A. K. Virmani, M. A. Spillman, V. Tonk, J. L. Blum, N. R. Schneider, I. I. Wistuba, J. W. Shay, J. D. Minna, and A. F. Gazdar. 1998. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 58:3237-3242.
66. Tsubouchi, H., and H. Ogawa. 2000. Exo1 roles for repair of DNA double-strand breaks and meiotic crossing over in Saccharomyces cerevisiae. Mol. Biol. Cell 11:2221-2233.
67. Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1997. Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene 14:2313-2321.[CrossRef][Medline]
68. Warbrick, E., P. J. Coates, and P. A. Hall. 1998. FEN1 expression: a novel marker for cell proliferation. J. Pathol. 186:319-324.[CrossRef][Medline]
69. Wellington, C. L., L. M. Ellerby, C. A. Gutekunst, D. Rogers, S. Warby, R. K. Graham, O. Loubser, J. van Raamsdonk, R. Singaraja, Y. Yang, J. Gafni, D. Bredesen, S. M. Hersch, B. R. Leavitt, S. Roy, D. W. Nicholson, and M. R. J. Hayden. 2002. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22:7862-7872.
70. Wu, X., T. E. Wilson, and M. R. Lieber. 1999. A role for FEN-1 in nonhomologous end joining: the order of strand annealing and nucleolytic processing events. Proc. Natl. Acad. Sci. USA 96:1303-1308.
71. Xie, Y., Y. Liu, J. L. Argueso, L. A. Henricksen, H.-I. Kao, R. A. Bambara, and E. Alani. 2001. Identification of rad27 mutations that confer differential defects in mutation avoidance, repeat tract instability, and flap cleavage. Mol. Cell. Biol. 21:4889-4899.
72. Yoon, J.-H., P. M. Swiderski, B. E. Kaplan, M. Takao, A. Yasui, B. Shen, and G. P. Pfeifer. 1999. Processing of UV damage in vitro by FEN-1 proteins as part of an alternative DNA excision repair pathway. Biochemistry 38:4809-4817.[CrossRef][Medline]
73. Zdraveski, Z. Z., J. A. Mello, M. G. Marinus, and J. M. Essigmann. 2000. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 7:39-50.[CrossRef][Medline]
This article has been cited by other articles:
